Rivaroxaban [15 mg and 20 mg film-coated tablet] for the prevention of myocardial infarction, cerebrovascular disease, and other cardiovascular events among patients with nonvalvular atrial fibrillation
Pre-Cycle 1 | DrugsHTA Council Recommendation (as of 18 April 2023)
The HTA Council recommends the government financing of dabigatran [110 mg and 150 mg capsule] for the prevention of myocardial infarction, cerebrovascular disease, and other cardiovascular events among patients with nonvalvular atrial fibrillation (NVAF) and subgroup of NVAF patients through their inclusion in the PNF.
Relevant Information
- Status: With Final HTA Council Recommendation and SOH Decision
- Topic Assignment: Internal Assessment
- Policy Question: Should rivaroxaban [15 mg and 20 mg film-coated tablet] for the prevention of myocardial infarction, cerebrovascular disease, and other cardiovascular events among patients with nonvalvular atrial fibrillation (NVAF) and subgroup of NVAF patients be funded by the government?
- Secretary of Health Decision: Approved as of 30 June 2023
Evidence and Relevant Documents